The stock of biotech company Arrowhead Pharmaceuticals (NASDAQ: ARWR) surged over 23% on the Wednesday before Thanksgiving, following the release of its fiscal 2025 earnings. The company reported revenues exceeding $829 million, a significant increase from $3.6 million in 2024, largely due to a rise in licensing and collaboration funds. This impressive performance reflects Arrowhead’s strengthened financial position and market confidence.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
